Hepatozelluläres Karzinom – Was ist neu?

Schlüsselwörter

hepatozelluäres Karzinom - Sorafenib - mRECIST - transarterielle Chemoembolisation - Gensignatur

Keywords

hepatocellular carcinoma - sorafenib - mRECIST - transarterial chemoembolisation - genetic signature

• Literatur

• 1 Abou-Alfa GK, Amadori D, Santoro A et al. Safety and efficacy of sorafenib in patients with hepatocellular carcinoma (HCC) and Child-Pugh A versus B cirrhosis. Gastrointest Cancer Res 2011; 4: 40-44
• 2 Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-1022
• 3 DuBray Jr BJ, Chapman WC, Anderson CD. Hepatocellular carcinoma: a review of the surgical approaches to management. Mo Med 2011; 108: 195-198
• 4 Edeline J, Boucher E, Rolland Y et al. Comparison of tumor response by response evaluation criteria in solid tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma. Cancer 2011; Jun 28. [Epub ahead of print]
• 5 Freise CE, Ferrell L, Liu T et al. Effect of systemic cyclosporine on tumor recurrence after liver transplantation in a model of hepatocellular carcinoma. Transplantation 1999; 67: 510-513
• 6 Hojo M, Morimoto T, Maluccio M et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 1999; 397: 530-534
• 7 Hollebecque A, Cattan S, Romano O et al. Safety and efficacy of sorafenib in hepatocellular carcinoma: the impact of the Child-Pugh score. Aliment Pharmacol Ther 2011; 34: 1193-1201
• 8 Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010; 30: 52-60
• 9 Liang W, Wang D, Ling X et al. Sirolimus-based immunosuppression in liver transplantation for hepatocellular carcinoma: A meta-analysis. Liver Transpl 2011; Sep 30. [Epub ahead of print]
• 10 Llovet JM, Ricci S, Mazzaferro V et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390
• 11 Maass T, Sfakianakis I, Staib F et al. Microarray-based gene expression analysis of hepatocellular carcinoma. Curr Genomics 2010; 11: 261-268
• 12 Marquardt JU, Galle PR, Teufel A. Molecular diagnosis and therapy of hepatocellular carcinoma (HCC): An emerging field for advanced technologies. J Hepatol 2011; Jul 23. [Epub ahead of print]
• 13 Marrero JA, Feng Z, Wang Y et al. Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology 2009; 137: 110-118
• 14 Pawlik TM, Reyes DK, Cosgrove D et al. Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma. J Clin Oncol 2011; 29: 3960-3967
• 15 Sherman M. Hepatocellular carcinoma: epidemiology, surveillance, and diagnosis. Semin Liver Dis 2010; 30: 3-16
• 16 Spangenberg HC, Thimme R, Blum HE. Serum markers of hepatocellular carcinoma. Semin Liver Dis 2006; 26: 385-390
• 17 Teufel A, Marquardt JU, Galle PR. Novel insights in the genetics of HCC recurrence and advances in transcriptomic data integration. J Hepatol 2011; Jul 23. [Epub ahead of print]
• 18 Teufel A, Staib F, Kanzler S et al. Genetics of hepatocellular carcinoma. World J Gastroenterol 2007; 13: 2271-2282
• 19 Toso C, Meeberg GA, Bigam DL et al. De novo sirolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma: long-term outcomes and side effects. Transplantation 2007; 83: 1162-1168
• 20 Villanueva A, Hoshida Y, Battiston C et al. Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma. Gastroenterology 2011; 140: 1501-1512 e1502
• 21 Worns MA, Weinmann A, Pfingst K et al. Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis. J Clin Gastroenterol 2009; 43: 489-495
• 22 Yau T, Yao TJ, Chan P et al. The significance of early alpha-fetoprotein level changes in predicting clinical and survival benefits in advanced hepatocellular carcinoma patients receiving sorafenib. Oncologist 2011; 16: 1270-1279